With over 0.28 million Reunion Neuroscience Inc. (REUN) shares trading Tuesday and a closing price of $1.43 on the day, the dollar volume was approximately $0.39 million. The shares have shown a negative half year performance of -44.14% and its price on 01/17/23 gained nearly 1.42%. Currently, there are 11.64M common shares owned by the public and among those 8.30M shares have been available to trade.
Insiders at the company have transacted a total of 16 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 800 shares. Insider sales of the common stock occurred on 14 occasions, with total insider shares sold totaling 16,252,933 shares.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
The top 3 mutual fund holders in Reunion Neuroscience Inc. are Horizons Psychedelic Stock Index, AdvisorShares Psychedelics ETF, and Arrow Canadian Advantage Alternat. Horizons Psychedelic Stock Index owns 0.28 million shares of the company’s stock, all valued at over $0.25 million. The company bought an additional 0.13 million shares recently to bring their total holdings to about 2.41% of the shares outstanding. AdvisorShares Psychedelics ETF bought 30000.0 shares to see its total holdings expand to 0.16 million shares valued at over $0.14 million and representing 1.38% of the shares outstanding. Arrow Canadian Advantage Alternat now owns shares totaling to 0.03% of the shares outstanding.
Shares of Reunion Neuroscience Inc. (NASDAQ: REUN) opened at $1.45, up $0.04 from a prior closing price of $1.41. However, the script later moved the day high at 1.5900, up 1.42%. The company’s stock has a 5-day price change of 6.92% and -33.49% over the past three months. REUN shares are trading 58.89% year to date (YTD), with the 12-month market performance down to -77.06% lower. It has a 12-month low price of $0.76 and touched a high of $7.62 over the same period. REUN has an average intraday trading volume of 28.73K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 24.82%, 11.36%, and -39.56% respectively.
Institutional ownership of Reunion Neuroscience Inc. (NASDAQ: REUN) shares accounts for 14.64% of the company’s 11.64M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $21.09M and a beta (3y monthly) value of 3.15. The earnings-per-share (ttm) stands at -$4.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.21% over the week and 12.97% over the month.
Analysts forecast that Reunion Neuroscience Inc. (REUN) will achieve an EPS of -$0.21 for the current quarter, -$0.21 for the next quarter and -$0.63 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.32 while analysts give the company a high EPS estimate of -$0.09. Comparatively, EPS for the current quarter was -$0.84 a year ago. Earnings per share for the fiscal year are expected to decrease by -35.50%, and 37.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Reunion Neuroscience Inc. (REUN) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
